DrugPatentWatch Database Preview
RAPIVAB Drug Profile
» See Plans and Pricing
Which patents cover Rapivab, and what generic alternatives are available?
Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.
This drug has sixty-one patent family members in twenty-eight countries.
The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.
US ANDA Litigation and Generic Entry Outlook for Rapivab
Rapivab was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 16, 2023. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for RAPIVAB
| International Patents: | 61 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 65 |
| Clinical Trials: | 2 |
| Patent Applications: | 59 |
| Drug Prices: | Drug price information for RAPIVAB |
| DailyMed Link: | RAPIVAB at DailyMed |
Generic Entry Opportunity Date for RAPIVAB
Generic Entry Date for RAPIVAB*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RAPIVAB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| BioCryst Pharmaceuticals | Phase 3 |
| Johns Hopkins University | Phase 4 |
| Department of Health and Human Services | Phase 4 |
US Patents and Regulatory Information for RAPIVAB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RAPIVAB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RAPIVAB
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 1040094 | Start Trial |
| Eurasian Patent Organization | 200870263 | Start Trial |
| Japan | 4102022 | Start Trial |
| South Africa | 9811595 | Start Trial |
| Japan | 6073202 | Start Trial |
| South Africa | 200809012 | Start Trial |
| China | 1282316 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
